 |
|
Pharmacological treatment of osteoporosis: 2022 update
Yunkyung Jeon, In-Joo Kim
J Korean Med Assoc. 2022;65(4):241-248. Published online 2022 Apr 10 DOI: https://doi.org/10.5124/jkma.2022.65.4.241
|
|
Citations to this article as recorded by
 Incidence and severity of medication-related osteonecrosis of the jaw in patients with osteoporosis using data from a Korean nationwide sample cohort in 2002 to 2019: a retrospective study
Su-Youn Ko, Tae-Yoon Hwang, Kiwook Baek, Chulyong Park
Journal of Yeungnam Medical Science.2024; 41(1): 39. CrossRef Cost-consequence analysis of continuous denosumab therapy for osteoporosis treatment in South Korea
Seungju Cha, Minjeong Sohn, Hyowon Yang, Eric J. Yeh, Ki-Hyun Baek, Jeonghoon Ha, Hyemin Ku
BMC Musculoskeletal Disorders.2024;[Epub] CrossRef Efficacy and Cardiovascular Safety of Romosozumab: A Meta-analysis and Systematic Review
Seo-Yong Choi, Jeong-Min Kim, Sang-Hyeon Oh, Seunghyun Cheon, Jee-Eun Chung
Korean Journal of Clinical Pharmacy.2023; 33(2): 128. CrossRef
|